Form 4: Abbott Laboratories Director Michael F. Roman Reports Stock Equivalent Unit Acquisition

Director Michael F. Roman reports acquisition of stock equivalent units in Abbott Laboratories due to director fees.

Summary

• On March 31, 2025, Michael F. Roman, a director of Abbott Laboratories, acquired 265 stock equivalent units.
• These units were obtained as director fees and are payable in cash generally at age 65 or upon retirement from the board.
• The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
• The price of the stock equivalent units was $132.65.
• Following the transaction, Roman directly owns 4,957 stock equivalent units, which includes units acquired through dividend reinvestment.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation and continued investment in the company.

Positives

• The acquisition of stock equivalent units reflects continued investment in Abbott Laboratories by a director.
• The dividend reinvestment feature contributes to the growth of the director's holdings.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director compensation and investment in the company.

Key Dates

Keywords

Stock Equivalent Units, Director Fees, Form 4, Abbott Laboratories, ABT, Michael F. Roman, Beneficial Ownership